Track topics on Twitter Track topics that are important to you
(MedPage Today) -- Push a button and, voila, dura tissue. Well, almost
Admedus Limited (ASX:AHZ) is expanding its regenerative tissue portfolio into additional large target repair markets following successful initial results from a pre-clinical study of ADAPT® treate...
WEST CHESTER, Pa., May 4, 2015 /PRNewswire/ -- DePuy Synthes CMF* today announced the launch of SYNTHECEL® Dura Repair, the first commercially available biosynthesized dural replacement derived f...
MEXICO CITY, Aug. 12, 2015 /PRNewswire/ -- IBM (NYSE: IBM) today announced its collaboration with Tienda Diabetes, a leading Mexican healthcare provider, to provide diabetes patients with af...
SOURCE July 21, 2015 While 3D bioprinting innovations sound life-saving and revolutionary, most are still years away from impacting ordinary people in regular hospitals. However, one Chinese company i...
DePuy Synthes CMF announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery.
A thin and flexible implant that can be applied directly to the surface of the spinal cord to administer electrical and chemical stimulation has been developed by scientists in Switzerland. The e-Dura...
Admedus Limited (ASX:AHZ) remains one of Morgans’ High Conviction calls in 2015, which also has an Add recommendation with a price target of A$0.20.The broker noted that with the A$28 million ca...